Using medical cannabis to relieve symptoms in patients with advanced pancreatic cancer
A Randomized Phase II Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Advanced Pancreatic and Colorectal Cancer (CanPan-C)
This study is testing if medical cannabis can help relieve symptoms like pain and nausea in people with advanced pancreatic cancer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | HealthPartners Institute Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Saint Louis Park, Minnesota) |
| Trial ID | NCT06605430 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of medical cannabis on symptom burden in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants will be randomly assigned to receive medical cannabis either immediately or after an 8-week delay, allowing researchers to compare symptom relief and quality of life outcomes between the two groups. The study will assess patient-reported outcomes and safety signals over a 16-week period, with a focus on understanding how cannabis can alleviate symptoms like nausea, pain, and anorexia. The goal is to provide evidence for a potential new treatment option for managing difficult symptoms associated with PDAC.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 or older with advanced PDAC who are experiencing significant symptoms and are starting systemic chemotherapy.
Not a fit: Patients who do not experience significant symptoms or who are not residents of Minnesota may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option for managing symptoms in patients with advanced pancreatic cancer, potentially improving their quality of life.
How similar studies have performed: While the use of medical cannabis for symptom management in cancer patients is being explored, this specific approach in advanced PDAC is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria 1. Adults (aged 18 or more at enrollment) 2. Histologically or cytologically proven pancreatic or colorectal cancer. Histologies may include listing of adenocarcinoma, poorly differentiated carcinoma, or other pathology terms that treating oncologist would consider managing per usual standard of care of pancreas and colorectal adenocarcinoma. Neuroendocrine tumors are excluded in both cancer types. 3. Advanced stage (locally advanced or metastatic) pancreatic or colorectal cancer with no definitive plans for curative surgery in the next 3 months 4. Self-report of experiencing nausea, vomiting, anorexia, cachexia (wasting), or pain at least once in the 14 days prior to randomization 5. Plan to initiate or initiated within the past 2 weeks standard-of-care systemic chemotherapy (any regimen that does not include immunotherapy) at a participating institution with no prior systemic therapy in the prior 3 months (prior adjuvant or neoadjuvant chemotherapy is allowed as long as it was \>3 months prior to randomization) 6. Must be a resident of Minnesota 7. Must be willing to be registered in the Minnesota Medical Cannabis Program and follow all rules and requirements of the state program 8. Must be willing to report baseline and required patient-reported outcomes Exclusion Criteria 1. Self-reported regular use (using 10 or more days in the 30 days prior to randomization) of a THC containing cannabinoid product 2. Patients with a history of intolerance or hypersensitivity to cannabis (i.e., cannabis hyperemesis) 3. Patients with Alzheimer's dementia, active epilepsy, or history of traumatic brain injury 4. Patients with known active or untreated brain metastases. A brain MRI is not required during the screening period. 5. Patients initiating or receiving immunotherapy, a chemotherapy-immunotherapy combination, or non-standard cytotoxic chemotherapy (including patients enrolled/ enrolling in trials of investigational cancer-directed treatments) 6. Women who are pregnant, breastfeeding or of childbearing potential without the use of birth control 7. Uncontrolled acute or chronic medical conditions, psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for enrollment in this study 8. Has any condition that in the opinion of the investigator might jeopardize the safety of the subject or interfere with protocol compliance
Where this trial is running
Saint Louis Park, Minnesota
- HealthPartners Cancer Research Center — Saint Louis Park, Minnesota, United States (Recruiting)
Study contacts
- Study coordinator: Alissa Gavenda, RN
- Email: cancercannabis@HealthPartners.com
- Phone: (952) 977-5555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.